Navigation Links
CSL Behring Parent Company, CSL Limited, Issues Fourth Corporate Responsibility Report
Date:12/3/2012

KING OF PRUSSIA, Pa., Dec. 3, 2012 /PRNewswire/ -- CSL Behring's parent company, CSL Limited (ASX: CSL), reaffirms the company's commitment to responsible business practice and sustainable development in its fourth Corporate Responsibility Report – Our Corporate Responsibility 2012. The report details CSL's performance across key corporate responsibility priority areas for the period July 1, 2011 through June 30, 2012.

(Logo: http://photos.prnewswire.com/prnh/20100914/PH63692LOGO

The priority areas include the Company's research into new and improved medicines, ensuring the safety and quality of its broad portfolio of therapies, providing a positive and healthy work environment for employees, behaving responsibly in the global marketplace, providing charitable support for communities in need around the world and minimizing the environmental impacts of its operations. Highlights of CSL's performance in these areas include:

  • Recognition of sustainable development and leadership by the FTSE4Good Index Series in 2011 and 2012 (FTSE4Good Index objectively measures the performance of companies that meet globally recognized corporate responsibility standards);
  • Research and Development investment of A$355 million dollars, with more than 30 clinical studies in operation across our portfolio of specialty and hemophilia products, breakthrough medicines and immunoglobulin-based products;
  • Economic contribution direct to local economies of more than A$4.2 billion, including global community (stakeholders and local communities) investment of A$35.4 million;
  • 2% growth in the total workforce with year-on-year reductions in recorded rates of lost time injury frequency and medical treatment injury frequency, including an 8% and 26% reduction from 2011, respectively;
  • 4% reduction in energy and water consumption and greenhouse gas emissions per unit of plasma production.

"CSL's reputation as one of the most innovative biopharmaceutical companies in the world and our continued growth are underscored by our commitment to conducting our business responsibly, and actively contributing to the well-being of our communities," said Dr. Brian McNamee, CEO and Managing Director of CSL Limited. "Our Corporate Responsibility Report for 2012 demonstrates this ongoing commitment."

About CSL Limited
Headquartered in Melbourne, Australia, CSL Limited (AUX: CSL) is a global biopharmaceutical company that develops, manufactures and markets biotherapies to prevent and treat rare and serious human diseases. CSL owns major facilities in Australia, Germany, Switzerland and the US, and employs over 11,000 people in more than 25 countries. For more information visit www.csl.com.au.

About CSL Behring
CSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant therapies worldwide.

CSL Behring therapies are used around the world to treat coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in the newborn. For more information visit http://www.cslbehring.com/. CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma.

View Our Corporate Responsibility 2012 at http://corporateresponsibility.csl.com.au/.

Contact:
Chris Florentz 
Manager, Corporate Communications
CSL Behring                                       
King of Prussia, PA                                                                            
+1 610 878 4316 

                           


'/>"/>
SOURCE CSL Behring
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. CSL Behring Initiates Study of Subcutaneous Administration of C1-esterase Inhibitor in Patients with Hereditary Angioedema
2. CSL Behring Announces FDA Filing of Biologics License Application for 4-Factor PCC for Urgent Reversal of Vitamin K Antagonist Anticoagulant Therapy
3. CSL Behring Receives FDA Orphan Drug Designation for rIX-FP, a Novel Therapy in Development to Treat Congenital Factor IX Deficiency (Hemophilia B)
4. Parent Project Muscular Dystrophy Endorses Senate Version of Prescription Drug User Fee Act After Patient Voice Strengthened
5. New Legislation To Make USPSTF More Transparent: Prostate Cancer Roundtable Supports Reform
6. Parents Less Likely To Develop Colds, Carnegie Mellon Research Shows
7. National Call-to-Action to Boost Meningitis Vaccination Rates Supported by Leading Health Organizations, Urges St. Louis Parents to Vaccinate Preteens and Teens
8. National Call-to-Action to Boost Meningitis Vaccination Rates Supported by Leading Health Organizations, Urges Nashville Parents to Vaccinate Preteens and Teens
9. National Call-to-Action to Boost Meningitis Vaccination Rates Supported by Leading Health Organizations, Urges Minneapolis-St. Paul Parents to Vaccinate Preteens and Teens
10. TUV Rheinland Confirms Apparent Fraud in Mislabeling of DRX Products Manufactured by HTRD and Excite Medical
11. Webcams Help Parents Keep Watch Over Their Babies During Hurricane Isaac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/5/2017)... , June 5, 2017 Kohll,s Pharmacy ... the United States . The Raizer is ... a fallen person up to an almost-standing position ... and operated by one assistant and does not ... is simple enough that a child can operate it, ...
(Date:6/1/2017)... Pa. , June 1, 2017 Nutriceutical ... and Veterinarian Recommended Solutions (VRS), and KD Pharma Group ... in Nutriceutical Holdings by KD Pharma Group. KD Pharma ... with the option to acquire the entire company. ... in KD. They are committed to growing the NH ...
(Date:5/30/2017)... TEL AVIV, Israel , May 30, 2017 /PRNewswire/ ... clinical stage pharmaceutical Company specializing in the development ... management will present a company overview at three ... The 7th Annual LD Micro Invitational: ... Date:                     ...
Breaking Medicine Technology:
(Date:6/27/2017)... BOSTON, MA (PRWEB) , ... June 27, 2017 , ... ... U.S. Senate bill to repeal and replace the 2010 Patient Protection and Affordable Care ... as compared with what would be expected under current law. , More than 20 ...
(Date:6/27/2017)... ... ... Two residents from the Gardant-managed assisted living and memory care communities in ... to protect Medicaid funding. , The video, which was produced by the American Health ... and Cathy Schwarz, a couple who is still able to see each other every ...
(Date:6/27/2017)... ... June 27, 2017 , ... Drs. Gregory ... hygiene symposium in Mystic, CT. Covering the process and maintenance strategies of gum ... these popular periodontal procedures. Drs. Toback and Urbanski practice as experienced periodontists ...
(Date:6/27/2017)... CA (PRWEB) , ... June 27, 2017 , ... ... orthodontic treatments . Orthodontics is a dental specialty that focuses on treating alignment ... Benefits include improved aesthetics and function. , North Hollywood dentist , ...
(Date:6/26/2017)... (PRWEB) , ... June 26, 2017 , ... Antoine Dental Center is now ... standard in tooth replacement and act as a support for prosthetic teeth, such as crowns, ... the existing bone and becomes a sturdy, lasting new root for the tooth. , ...
Breaking Medicine News(10 mins):